HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Experimental Diabetes Mellitus

Diabetes mellitus induced experimentally by administration of various diabetogenic agents or by PANCREATECTOMY.
Also Known As:
Diabetes Mellitus, Experimental; Diabete, Streptozocin; Diabetes, Alloxan; Diabetes, Streptozocin; Diabetes, Streptozotocin; Streptozocin Diabete; Alloxan Diabetes; Streptozocin Diabetes; Streptozotocin Diabetes
Networked: 1609 relevant articles (37 outcomes, 130 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Body Weight (Weight, Body)
2. Inflammation
3. Vascular Dementia (Subcortical Arteriosclerotic Encephalopathy)
4. Diabetes Mellitus
5. Hypoglycemia (Reactive Hypoglycemia)

Experts

1. Rassokhina, L M: 8 articles (03/2015 - 03/2009)
2. Patel, Samir P: 7 articles (03/2008 - 01/2006)
3. Katyare, Surendra S: 7 articles (03/2008 - 01/2006)
4. Sybirna, N O: 6 articles (07/2015 - 09/2006)
5. Volchegorskiń≠, I A: 6 articles (01/2014 - 11/2008)
6. Shpakov, A O: 5 articles (03/2015 - 01/2005)
7. Brodiak, I V: 5 articles (01/2014 - 09/2006)
8. Vallon, Volker: 5 articles (01/2014 - 01/2002)
9. Miroshnichenko, I Iu: 5 articles (01/2014 - 03/2009)
10. Prysiazhna, O D: 5 articles (01/2008 - 01/2003)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Experimental Diabetes Mellitus:
1. Insulin (Novolin)FDA Link
2. Glucose (Dextrose)FDA LinkGeneric
3. AlloxanIBA
4. Blood Glucose (Blood Sugar)IBA
5. DNA (Deoxyribonucleic Acid)IBA
6. Glutathione (Reduced Glutathione)IBA
7. HexosesIBA
8. Cysteine (L-Cysteine)FDA Link
9. Streptozocin (Streptozotocin)FDA Link
10. FructoseIBA

Therapies and Procedures

1. Transplantation (Transplant Recipients)
2. Islets of Langerhans Transplantation
3. Intramuscular Injections
4. Transplants (Transplant)
03/01/2008 - "Sixty inbred male Lewis rats were assigned to four experimental groups: NC-15 nondiabetic control rats; DC-15 untreated diabetic control rats; PT1-15 diabetic rats that received syngeneic pancreas transplants 2 weeks after alloxan diabetes induction; PT2-15 diabetic rats that received pancreas transplants 12 weeks after diabetes onset. "
03/01/1964 - "[PANCREAS GRAFT IN THE ANTERIOR CHAMBER OF THE EYE OF THE RAT WITH ALLOXAN DIABETES]."
03/01/1964 - "[SUBCONJUNCTIVAL PANCREATIC GRAFT IN A RAT WITH ALLOXAN DIABETES]."
02/01/1988 - "To compare the long-term effectiveness of whole pancreas transplantation and pancreatic islet transplantation in controlling the metabolic disorders of alloxan diabetes, metabolic studies were performed monthly for 2 years in 4 groups of highly inbred rats: (1) NC-116 nondiabetic controls; (2) DC-273 untreated alloxan-diabetic controls; (3) PDT-182 rats that received syngeneic pancreaticoduodenal transplants shortly after induction of diabetes with alloxan; and (4) IT-92 rats that received an intraportal injection of at least 1500, but usually 2000, syngeneic pancreatic islets shortly after induction of diabetes with alloxan. "
09/01/1987 - "To compare the long-term effectiveness of whole pancreas transplantation and pancreatic islet transplantation in controlling the metabolic disorders and preventing the kidney lesions of alloxan diabetes, metabolic and morphologic studies were performed in four groups of rats: (1) NC-116 nondiabetic controls; (2) DC-273 untreated alloxan-diabetic controls; (3) PDT-182 rats that received syngeneic pancreaticoduodenal transplants not long after induction of diabetes with alloxan; and (4) IT-92 rats that received an intraportal injection of at least 1500 and usually 2000 syngeneic pancreatic islets soon after induction of diabetes with alloxan. "
5. Pancreas Transplantation
07/01/1980 - "Prevention by whole pancreas transplantation of glomerular basement membrane thickening in alloxan diabetes."
03/01/1974 - "Recovery from experimental diabetes mellitus in mice after pancreas transplantation."
04/01/2000 - "In conclusion, in a rat model with streptozotocin-diabetes and pancreas transplantation but no need for immunosuppression, both systemic and portal venous drainage avoid peripheral and hepatic insulin resistance; also, there is no increased risk for atherosclerosis."
02/01/1988 - "To compare the long-term effectiveness of whole pancreas transplantation and pancreatic islet transplantation in controlling the metabolic disorders of alloxan diabetes, metabolic studies were performed monthly for 2 years in 4 groups of highly inbred rats: (1) NC-116 nondiabetic controls; (2) DC-273 untreated alloxan-diabetic controls; (3) PDT-182 rats that received syngeneic pancreaticoduodenal transplants shortly after induction of diabetes with alloxan; and (4) IT-92 rats that received an intraportal injection of at least 1500, but usually 2000, syngeneic pancreatic islets shortly after induction of diabetes with alloxan. "
09/01/1987 - "To compare the long-term effectiveness of whole pancreas transplantation and pancreatic islet transplantation in controlling the metabolic disorders and preventing the kidney lesions of alloxan diabetes, metabolic and morphologic studies were performed in four groups of rats: (1) NC-116 nondiabetic controls; (2) DC-273 untreated alloxan-diabetic controls; (3) PDT-182 rats that received syngeneic pancreaticoduodenal transplants not long after induction of diabetes with alloxan; and (4) IT-92 rats that received an intraportal injection of at least 1500 and usually 2000 syngeneic pancreatic islets soon after induction of diabetes with alloxan. "